A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RGT001-075 Compared With Placebo in Adult Patients With Obesity or Overweight With Weight-Related Comorbidities
Latest Information Update: 30 Jan 2026
At a glance
- Drugs RGT 075 (Primary)
- Indications Obesity
- Focus Adverse reactions; Proof of concept
- Sponsors Regor Therapeutics
Most Recent Events
- 10 Jan 2025 Status changed from active, no longer recruiting to completed, According to Regor Therapeutics media release.
- 10 Jan 2025 Topline results presented in the Regor Therapeutics Media Release.
- 28 May 2024 Status changed from recruiting to active, no longer recruiting.